Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Maxwell Biotech Venture Fund (MBVF)

May 2012
Maxwell Biotech Venture Fund (MBVF), a Russian venture fund company that invests in the life sciences sector, has opened an office in Boston at 420 Boylston St. MBVF is a $100 million fund earmarked for investments in medical innovations and biotechnology. Begun as a public-private partnership between Russian Venture Company (RVC) and private investors, it is managed by Maxwell Asset Management. Transactions undertaken by MBVF have included investments and licensing collaborations with US companies Sequella, AtheroNova, Bionevia and Dental Photonics. MBVF representatives will be working with colleagues from RVC USA Inc.

AltheroNovaAmericasBioneviaBiophotonicsbiophotonics in dentistrybiotechnologyBusinessDental Photonicslife sciences researchMassachusettsMaxwell Asset ManagementMaxwell Biotech Venture FundMBVFMiddle EastRapidScanRussiaRussian Venture CompanyRVCRVC USASequella

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x Subscribe to BioPhotonics magazine - FREE!